Related Experiment Video
Updated: Feb 10, 2026

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes
Published on: March 3, 2020
Potential of Continuous Manufacturing for Liposomal Drug Products
Robert D Worsham1,2, Vaughan Thomas2, Suzanne S Farid2
1Insmed Inc., 10 Finderne Ave, Bridgewater, NJ, US.
Abstract:
Over the last several years, continuous manufacturing of pharmaceuticals has evolved from bulk APIs and solid oral dosages into the more complex realm of biologics. The development of continuous downstream processing techniques has allowed biologics manufacturing to realize the benefits (e.g., improved economics, more consistent quality) that come with continuous processing. If relevant processing techniques and principles are selected, the opportunity arises to develop continuous manufacturing designs for additional pharmaceutical products including liposomal drug formulations. Liposome manufacturing has some inherent aspects that make it favorable for a continuous process. Other aspects such as formulation refinement, materials of construction, and aseptic processing need development, but present an achievable challenge. This paper reviews the current state of continuous manufacturing technology applicable to liposomal drug product manufacturing and an assessment of the challenges and potential of this application.
Related Concept Videos
Drug Product Stability
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Drug Products: Biologics, Biosimilars and Interchangeables
Steel Manufacturing
During this smelting process, limestone plays a crucial role by forming slag. Slag captures impurities within the molten iron, such...
Drug Product Performance: In Vitro–In Vivo Correlation

